Prior Funded

  • Pratibha Nerurkar, PhD

    Pratibha Nerurkar, PhD

    Associate Professor, Department of Molecular Biosciences & Bioengineering, University of Hawai‘i Mānoa

    Research Areas: 

    Selected Publications: 

    Kumar M, Roe K, Nerurkar PV, Namekar M, Orillo B, Verma S, Nerurkar VR. Impaired virus clearance, compromised immune response and increased mortality in type 2 diabetic mice infected with west nile virus. PLoS One. 2012; 7(8):e44682.
    Nerurkar PV, Nishioka A, Eck PO, Johns LM, Volper E, Nerurkar VR. Regulation of glucose metabolism via hepatic forkhead transcription factor 1 (FoxO1) by Morinda citrifolia (noni) in high-fat diet-induced obese mice. Br J Nutr. 2012 Jul 108(2):218-28.
    Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter Melon Extract Impairs Prostate Cancer Cell-Cycle Progression and Delays Prostatic Intraepithelial Neoplasia in TRAMP Model. Cancer Prev Res (Phila). 2011 Dec; 4(12):2122-30.
    Snee LS, Nerurkar VR, Dooley DA, Efird JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management. Nutr J. 2011; 10:78.
    Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, Shah P, Feher D, Williams PG, Nerurkar VR. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation. 2011; 8:64.
    Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med. 2010; 10:34.
    Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010 Jun; 27(6):1049-53.
    Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 2010 Mar 1; 70(5):1925-31.
    Nerurkar PV and Nerurkar VR. Respected Sir(2): magic target for diabetes. Cellscience 2008; 4(4): 82-96.
    Nerurkar PV and Nerurkar VR. Can Sir(2) regulate cancer? Cellscience 2008; 4(4): 50-56.
    Nerurkar PV, Lee Y-K, Motosue M, Adeli K and Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008 Mar 5:1-9.
    Lim S, Dragull K, Tang CS, Bittenbender S and Nerurkar PV. Effects of Kava Alkaloid, Pipermethystine (PM), and Kavalactones on Oxidative Stress and Hepatic Cytochrome P450 in F344 Rats. Toxi. Sci., 2007; 97(1):214-21.
    Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J and Nerurkar VR. Lipid lowering effects of Momordica charantia (bitter melon) on cellular lipids and apolipoproteins in protease inhibitor-treated human hepatoma cells. Br J Pharmacol. 2006 Aug;148(8):1156-64. Epub 2006 Jul 3.
    Nerurkar PV, Pearson L, Efird J, Adeli K, Theriault A. and Nerurkar VR. Inhibition of microsomal triglyceride transfer protein (MTP) gene expression and ApoB secretion by bitter melon in HepG2 Cells. Journal of Nutrition, 2005; 135: 702-706.
    PubMed Publications Listing:  Nerurkar PV  |  Nerurkar P